Article info
PDFCorrespondence
Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al
- Correspondence to Dr Theo Rispens, Immunopathology, Sanquin Research, Amsterdam, The Netherlands; t.rispens{at}sanquin.nl
Citation
Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al
Publication history
- Received October 29, 2019
- Accepted November 1, 2019
- First published November 19, 2019.
Online issue publication
January 27, 2022
Article Versions
- Previous version (27 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.